NLS Pharmaceutics Regains Nasdaq Bid Price Compliance
Ticker: NCEL · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | bullish |
Sentiment: bullish
Topics: compliance, listing, nasdaq
TL;DR
NLS Pharma back above $1 for 10 days, Nasdaq compliance regained.
AI Summary
NLS Pharmaceutics Ltd. announced on October 10, 2024, that it believes it has regained compliance with Nasdaq's minimum bid price requirement. This is due to its common shares trading above $1.00 for ten consecutive trading days.
Why It Matters
Regaining compliance with Nasdaq's minimum bid price is crucial for NLS Pharmaceutics to maintain its listing on the exchange, avoiding potential delisting.
Risk Assessment
Risk Level: medium — While regaining compliance is positive, the company's ability to sustain the bid price and its overall financial health remain key factors.
Key Numbers
- $1.00 — Minimum Bid Price (The threshold NLS Pharmaceutics' common shares needed to exceed for ten consecutive trading days to regain Nasdaq compliance.)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — The company filing the report and regaining compliance.
- Nasdaq (company) — The stock exchange whose listing rules were addressed.
- $1.00 (dollar_amount) — The minimum bid price requirement for Nasdaq compliance.
- October 10, 2024 (date) — The date as of which compliance is believed to be regained.
FAQ
What specific date did NLS Pharmaceutics Ltd. believe it regained compliance with the Nasdaq minimum bid price requirement?
NLS Pharmaceutics Ltd. believes it regained compliance as of October 10, 2024.
What is the Nasdaq rule NLS Pharmaceutics Ltd. is addressing?
The company is addressing Nasdaq Listing Rule 5550(a)(2), which pertains to the minimum bid price requirement.
For how many consecutive trading days did NLS Pharmaceutics' common shares trade above $1.00?
The company's common shares traded above $1.00 for ten consecutive trading days.
What is the principal executive office address of NLS Pharmaceutics Ltd.?
The principal executive offices are located at The Circle 6, 8058 Zurich, Switzerland.
Which registration statements on Form F-3 are referenced in this filing?
The filing references Registration Statements on Form F-3 with file numbers 333-262489, 333-268690, and 333-269220.
Filing Stats: 251 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2024-10-10 16:01:16
Key Financial Figures
- $1.00 — hat its common shares have traded above $1.00 for ten consecutive trading days. This
Filing Documents
- ea0217306-6k_nlspharma.htm (6-K) — 15KB
- 0001213900-24-086884.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: October 10, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2